InterVenn

OverviewSuggest Edit

InterVenn is a life sciences and technology company developing an AI-driven mass spectrometry platform. Its approach combines the analysis of glycoproteomics using mass spectrometry with data science and artificial intelligence to identify potentially actionable and clinically relevant information for conditions including cancers, autoimmunity, fibrosis, and neurodegeneration.

TypePrivate
Founded2017
HQSouth San Francisco, CA, US
Websiteintervenn.bio

Latest Updates

Employees (est.) (Jan 2021)49(+5%)
Cybersecurity ratingAMore

Key People/Management at InterVenn

Erwin Estigarribia

Erwin Estigarribia

COO
Aldo Carrascoso

Aldo Carrascoso

Co-Founder & CEO
Klaus Lindpaintner

Klaus Lindpaintner

Chief Scientific and Medical Officer
Show more

InterVenn Office Locations

InterVenn has offices in South San Francisco and Redwood City
South San Francisco, CA, US (HQ)
2 Tower Pl 5th floor
Redwood City, CA, US
800 Chesapeake Dr
Show all (2)

InterVenn Financials and Metrics

Summary Metrics

Founding Date

2017

InterVenn total Funding

$43.4 m

InterVenn latest funding size

$34 m

Time since last funding

2 months ago

InterVenn investors

InterVenn's latest funding round in November 2020 was reported to be $34 m. In total, InterVenn has raised $43.4 m
Show all financial metrics

InterVenn Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

InterVenn Online and Social Media Presence

Embed Graph

InterVenn News and Updates

InterVenn Biosciences Raises $34 Million To Commercialize Glycoproteomic LDT For Ovarian Cancer And Immuno-Oncology

The Life Sciences team advised InterVenn Biosciences on its $34 million Series B fundraising. The latest round was led by Anzu Partners with full participation of Genoa Ventures, Amplify Partners, and True Ventures; Xeraya Capital and the Ojjeh Family joined the syndicate as well.read more

InterVenn Biosciences raises $34 million to accelerate cancer test development with AI

InterVenn Biosciences, a company developing an AI-imbued platform for diagnostic cancer test design, raised $34 million.

InterVenn Blogs

InterVenn Biosciences Raises $34M to Commercialize Glycoproteomic LDT for Ovarian Cancer and Immuno-oncology; taps John Leite, Ph.D., as Chief Business Officer

Company looks to validate first of its kind LDTs intended for immediate clinical use and drive rapidly expanding partnership projects. SOUTH SAN FRANCISCO, Calif.–InterVenn Biosciences today announced it has raised $34M in a Series B fundraising. The latest round was led by Anzu Partners with full p…

VOCAL Study, a Malaysian Perspective

Happy Malaysia Day (16th September 2019) to all Malaysians! On behalf of InterVenn Biosciences (InterVenn), I wish all Malaysians unity, prosperity, and importantly, happiness and good health! On this auspicious day, I would like to take some time to reflect on InterVenn’s efforts and contributions …

InterVenn Frequently Asked Questions

  • When was InterVenn founded?

    InterVenn was founded in 2017.

  • Who are InterVenn key executives?

    InterVenn's key executives are Erwin Estigarribia, Aldo Carrascoso and Klaus Lindpaintner.

  • How many employees does InterVenn have?

    InterVenn has 49 employees.

  • Who are InterVenn competitors?

    Competitors of InterVenn include Berdac, Travecta Therapeutics and Unlearn.AI.

  • Where is InterVenn headquarters?

    InterVenn headquarters is located at 2 Tower Pl 5th floor, South San Francisco.

  • Where are InterVenn offices?

    InterVenn has offices in South San Francisco and Redwood City.

  • How many offices does InterVenn have?

    InterVenn has 2 offices.